Biohit Oyj to expand analyzer retail
March 12, 2013 at 3 P.M. (EET)
Finnish healthcare company Biohit Oyj and American company Gold Standard Diagnostics Corp. have signed an agreement for the analyzers distributionship. The agreement gives Biohit Oyj rights to sell the Gold Standard Diagnostics' manufactured automated ELISA analyzer (worldwide, excluding the U.S., Puerto Rico and China).
The ELISA analyzer (enzyme-linked immunosorbent assay analyzer), as part of the Biohit product portfolio, will improve the availability of GastroPanel test. With the help of integrated system solution small and medium-sized laboratories are able to provide GastroPanel testing easily and cost-effectively. Automated systems save time and resources, eliminate human errors, increase work safety and ensure high-quality analyses.
CEO Semi Korpela, Biohit Oyj: "The partnership supports commercialization of our diagnostic products and GastroPanel. The new analyzer, as part of our product portfolio, strengthens our ability to provide an easy-to-use complete automated analyzer system to laboratories."
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”. The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to responsibility and it is our duty to innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki and its subsidiaries are located China and UK. Since 1999, Biohit’s Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.